Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction
Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction
复制标题
DOI：
10.1016/s0022-5347(05)00483-0
复制
发表时间：
2006-03-01
影响因子：
6.6
通讯作者：
Millard, R
中科院分区：
文献类型：
--
作者：
Abrams, P;Kaplan, S;Millard, R
目的：男性 OAB 和 BOO 患者的抗毒蕈碱治疗被认为存在尿潴留的潜在风险。使用压力流尿动力学，我们评估了托特罗定与安慰剂对 OAB 和 BOO 男性的安全性。 材料和方法：患有 BOO 且确诊逼尿肌过度活动的男性（40 岁以上）被随机分配到托特罗定（149 名患者每天两次，每次 2 毫克）或安慰剂（72 名患者），持续 12 周。主要终点为 Qmax 和 pdetQmax。结果：Qmax（-0.7 ml/秒，95% CI -1.6 至 0.4）和 pdetQmax（-7 cm H2O，95% CI -3 至 11）的中位治疗差异具有可比性。与安慰剂相比，托特罗定显着降低了 BOOI（-9 vs 0，p
Purpose: Antimuscarinic therapy for men with OAB and BOO is perceived as a potential risk for urinary retention. Using pressure flow urodynamics, we evaluated the safety of tolterodine vs placebo in men with OAB and BOO.Materials and Methods: Men (older than 40 years) with BOO and confirmed detrusor overactivity were randomized to tolterodine (2 mg twice daily in 149) or placebo (in 72) for 12 weeks. Primary end points were Qmax and pdetQmax.Results: Median treatment differences in Qmax (-0.7 ml per second, 95% CI -1.6 to 0.4) and pdetQmax (-7 cm H2O, 95% CI -3 to 11) were comparable. Tolterodine significantly reduced the BOOI vs placebo (-9 vs 0, p